--- title: "What's Going On With Iovance Biotherapeutics Stock On Friday?" type: "News" locale: "en" url: "https://longbridge.com/en/news/278150248.md" description: "Iovance Biotherapeutics Inc. (NASDAQ:IOVA) stock rose 14.52% to $5.24 on Friday, despite no news. Investors are monitoring high short interest at 39.6% and positive early data from a TIL cell therapy trial showing a 50% response rate. The company plans to initiate a registrational trial in 2026 and engage with the FDA for expedited approval. The stock is currently 59.6% above its 20-day SMA and 98.5% above its 100-day SMA, indicating strong momentum, though it may be overbought. Analysts rate it a Buy with an average target of $11.23." datetime: "2026-03-06T18:06:48.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/278150248.md) - [en](https://longbridge.com/en/news/278150248.md) - [zh-HK](https://longbridge.com/zh-HK/news/278150248.md) --- # What's Going On With Iovance Biotherapeutics Stock On Friday? **Iovance Biotherapeutics Inc.** (NASDAQ:IOVA) stock is trading higher on Friday, with no news to justify the movement. Investors should note the company’s short interest sits as high as 39.6%, with a market capitalization of 1.66 billion, according to Benzinga Pro data. Last week, the company shared positive early data from a pilot clinical trial for its TIL cell therapy in advanced soft-tissue sarcomas. ## 50% Response Rate in TIL Therapy Trial The trial, conducted by Memorial Sloan Kettering Cancer Center, reported a 50% confirmed objective response rate among the first six evaluable patients treated with lifileucel monotherapy. Iovance plans to initiate a single-arm registrational trial in the second quarter of 2026 and engage with the U.S. Food and Drug Administration (FDA) for expedited approval, highlighting a significant market opportunity as over 8,000 patients are diagnosed annually in the U.S. and Europe. Additionally, the company aims to explore lifileucel in other high-grade soft tissue sarcoma subtypes, further expanding its potential market reach. ## IOVA’s Strong Year-Over-Year Momentum The stock is currently trading 59.6% above its 20-day SMA and 98.5% above its 100-day SMA, demonstrating strong momentum over the past year. Shares have increased 34.80% over the past 12 months and are currently positioned closer to their 52-week highs than lows. The RSI is at 83.41, which is considered overbought territory, indicating that the stock may be due for a pullback. Meanwhile, MACD is at 0.4295, above its signal line at 0.2853, suggesting bullish momentum in the stock. The combination of overbought RSI and bullish MACD indicates that while the stock is experiencing strong upward momentum, it may be approaching a point where profit-taking could occur. - **Key Resistance**: $5.50 - **Key Support**: $4.50 **Analyst Consensus & Recent Actions:** The stock carries a Buy Rating with an average price target of $11.23. Recent analyst moves include: - **UBS**: Neutral (Raises Target to $4.00) (Mar. 5) - **Citizens**: Upgraded to Market Outperform (Target $5.00) (Mar. 3) - **Barclays**: Overweight (Raises Target to $11.00) (Feb. 25) **IOVA Price Action:** Iovance Biotherapeutics shares were up 14.52% at $5.24 at the time of publication on Friday. The stock is trading at a new 52-week high, according to Benzinga Pro data. _Image via Shutterstock_ ### Related Stocks - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [IOVA.US](https://longbridge.com/en/quote/IOVA.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) ## Related News & Research - [BUZZ-Allogene tumbles on $175 mln stock offering after cancer therapy data](https://longbridge.com/en/news/282722450.md) - [BUZZ-Cancer biotech Adlai Nortye jumps after $150 mln equity financing](https://longbridge.com/en/news/282996483.md) - [Sana Announces Strategic Collaboration With Mayo Clinic For Developing Type-1 Diabetes Therapy SC451](https://longbridge.com/en/news/282645188.md) - [Fate Therapeutics Details Off-the-Shelf CAR T Progress in Lupus and Solid Tumors at Needham Conference](https://longbridge.com/en/news/282940584.md) - [FDA Rejection Sparks Questions On Replimune Drug Approval Path](https://longbridge.com/en/news/282577359.md)